Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD6234 in Overweight or Obese Adults With Type 2 Diabetes on GLP-1 RA
NCT06851858Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2025
- Primary completion
- May 2026
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of lenbelintide in obesity, type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started Mar 2025; status: completed.
02
Drugs
lenbelintide
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06851858.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06851858.